A pharmaceutical composition and method for regenerating cardiomyocytes in
treating or repairing heart muscle damages or injuries caused by an
ischemic disease. The pharmaceutical composition contains an active
ingredient compound with a backbone structure of Formula (I). The active
ingredient compound is capable of (a) increasing viability of myogenic
precursor cells to enable said precursor cells to survive through an
absolute ischemic period; (b) reconstituting a damaged blood supply
network in said heart region where said injured muscle is located; and
(c) enhancing cardiomyogenic differentiation efficiency of said precursor
cells down cardiac linage, said steps being performed simultaneously or
in any particular order.